Continuous Hemodynamic Response to Angiotensin II in Critically Ill Pediatric Patients: A Single Center Cohort Study.

ABSTRACT:

Objective

To report efficacy, safety, and dosing of angiotensin II (AT-II) in pediatric patients with refractory vasodilatory shock.

Methods

This was a single center retrospective cohort study using automated, high-fidelity hemodynamic data in a large tertiary pediatric academic medical center. Pediatric patients who required multimodal vasopressor therapy for fluid refractory vasodilatory shock and received AT-II between June 2017 and November 2022 were included. High-fidelity hemodynamic data were captured via the Etiometry T3 platform. Vasoactive-inotropic score (VIS), AT-II dosing, demographics, clinical characteristics, and potential adverse effects were collected from the electronic medical record.

Results

Fourteen pediatric patients with a median age of 11.6 ye

SUBMITTER: Dotolo N 

PROVIDER: S-EPMC12533705 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature